Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

High-dose melphalan plus autologous stem-cell transplantation (ASCT) is the standard approach in transplant-eligible patients with newly diagnosed myeloma. Our aims were to compare consolidation with high-dose melphalan plus ASCT versus chemotherapy (cyclophosphamide and dexamethasone) plus lenalidomide, and maintenance with lenalidomide plus prednisone versus lenalidomide alone.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Dec 2015

Volume: 16

Issue: 16

Affiliations

[1 ] Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.

[2 ] Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.

[3 ] Divisione di Ematologia, Azienda Policlinico-OVE, Università di Catania, Catania, Italy.

[4 ] Policlinico Universitario Federico II, Naples, Italy.

[5 ] Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

[6 ] UOC Ematologia Ospedale S Eugenio, Rome, Italy.

[7 ] Department of Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.

[8 ] UOC Ematologia IRCCS AOU San Martino-IST, Genoa, Italy.

[9 ] Hematology Department, Niquarda Ca'Granda Hospital, Milan, Italy.

[10 ] Unit of Clinical Epidemiology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino and CPO Piemonte, Turin, Italy.

[11 ] Ematologia e Centro TMO Ospedale Centrale Bolzano, Bolzano, Italy.

[12 ] Haematology Department, Cancer Services, Barwon Health, Geelong, VIC, Australia.

[13 ] A O S Maria di Terni, S C Oncoematologia, Terni, Italy.

[14 ] Division of Hematology, Ospedali Riuniti, Ancona, Italy.

[15 ] University of Bari Aldo Moro Medical School, Department of Biomedical Science, Internal Medicine G Baccelli Policlinico, Bari, Italy.

[16 ] Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie, U O Ematologia Clinica, Ospedale Civile Spirito Santo, Pescara, Italy.

[17 ] Azienda O U di Udine, DISM, Università di Udine, Udine, Italy.

[18 ] Department of Haematooncology, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic.

[19 ] Department of Clinical Haematology, Alfred Health, Monash University, Melbourne, VIC, Australia.

[20 ] Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy. Electronic address: appalumbo@yahoo.com.

Article

Publisher Item ID: S1470-2045(15)00389-7

DOI: 10.1016/S1470-2045(15)00389-7

PubMed ID: 26596670

SO-VID: f33941f1-32af-447a-9f72-abecc78892ca

History

Data availability:

Comments

Comment on this article

scite_

Cited by 106

See all cited by

- Version 1